Vaidya Sane Ayurved Laboratories Ltd
Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running
of hospitals & clinics, and sale of Ayurved based medicines[1]
- Market Cap ₹ 169 Cr.
- Current Price ₹ 161
- High / Low ₹ 335 / 147
- Stock P/E 18.8
- Book Value ₹ 83.2
- Dividend Yield 0.00 %
- ROCE 15.1 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Working capital days have increased from 41.3 days to 112 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 99 | 99 | 90 | 107 | |
| 91 | 95 | 76 | 91 | |
| Operating Profit | 9 | 5 | 13 | 15 |
| OPM % | 9% | 4.5% | 15% | 14% |
| 1 | 2 | 1 | 2 | |
| Interest | 1 | 0 | 0 | 1 |
| Depreciation | 3 | 3 | 4 | 6 |
| Profit before tax | 6 | 3 | 10 | 11 |
| Tax % | 25% | 30% | 28% | 17% |
| 5 | 2 | 7 | 9 | |
| EPS in Rs | 4.59 | 1.88 | 6.80 | 8.55 |
| Dividend Payout % | 5% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 3% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -19% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 |
| Reserves | 30 | 45 | 52 | 77 |
| 0 | 2 | 1 | 3 | |
| 14 | 12 | 13 | 14 | |
| Total Liabilities | 55 | 70 | 77 | 105 |
| 21 | 28 | 34 | 35 | |
| CWIP | 2 | 2 | 1 | 2 |
| Investments | 15 | 18 | 21 | 40 |
| 17 | 21 | 20 | 28 | |
| Total Assets | 55 | 70 | 77 | 105 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0 | -1 | 11 | 5 | |
| 1 | -13 | -10 | -24 | |
| -1 | 15 | -1 | 17 | |
| Net Cash Flow | -1 | 1 | -0 | -2 |
| Free Cash Flow | -7 | -12 | 2 | -2 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 31% | -9% | 93% | 49% |
Ratios
Consolidated / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 22 | 22 | 31 | 35 |
| Inventory Days | 58 | 82 | 70 | |
| Days Payable | 101 | 149 | 127 | |
| Cash Conversion Cycle | 22 | -20 | -37 | -21 |
| Working Capital Days | -2 | 5 | 7 | 112 |
| ROCE % | 6% | 18% | 15% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Number of Franchise Clinics Count |
|
||||
| Number of Insurance Companies Empanelled Count |
|||||
| Total Number of Clinics Count |
|||||
| Total Number of Hospital Beds Count |
|||||
| New Patient Footfall Count |
|||||
| Total Patient Footfall Count |
|||||
| Care Plans Sold Count |
|||||
Extracted by Screener AI
Documents
Announcements
-
General Updates
- Madhavbaug signed MoU with Parul Institute of Ayurved for research, training and product development collaboration.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
- Company states corporate governance provisions are not applicable for quarter ended September 30, 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Regulation 74(5) certificate for quarter ended 30 September 2026; no rematerialisation requests received.
-
Shareholders meeting
- 27th AGM voting results: 11 resolutions passed on September 30, 2026, including director reappointments and MD remuneration increase.
-
Shareholders meeting
- 27th AGM approved audited FY26 financials, director reappointments, auditors, and VSAL-ESOP 2026.
Annual reports
-
Annual Report 2024
from nse
-
Annual Report 2023
from nse
-
Annual Report 2022
from nse
Concalls
-
May 2026PPT REC
-
Nov 2025Transcript PPT
-
May 2025Transcript PPT
-
Nov 2024Transcript
-
Jun 2024Transcript PPT
-
May 2024PPT
-
Nov 2023PPT
-
Nov 2023Transcript PPT REC
-
Nov 2023Transcript PPT
-
May 2023PPT
-
Nov 2022PPT
Business Overview:[1][2]
Vaidya Sane Ayurved Laboratories Ltd. (Madhavbaug)
is one of India’s leading chains of cardiac care
clinics and hospitals, offering non-invasive,
Ayurveda-based treatments for chronic conditions
such as heart disease, diabetes, hypertension, obesity,
and joint pain. The company combines traditional Ayurvedic
therapies with modern diagnostics and technology, supported
by in-house manufacturing of Ayurvedic medicines and nutritional products.
Its business model comprises three segments—clinics, hospitals, and products. The patients undergo a standardised 12-month treatment protocol, consisting of an intensive 3-month phase followed by a 9-month maintenance phase, incorporating Panchakarma, customised diet kits, and herbal medicines.